(FBIO) Fortress Biotech - Overview
Stock: Dermatology Drugs, Pain Therapy, Oncologic Agents, Vaccines, Gene Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 100% |
| Relative Tail Risk | -15.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.09 |
| Alpha | 63.26 |
| Character TTM | |
|---|---|
| Beta | 0.650 |
| Beta Downside | 0.777 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.48% |
| CAGR/Max DD | -0.38 |
Description: FBIO Fortress Biotech December 22, 2025
Fortress Biotech (NASDAQ:FBIO) is a U.S.-based biopharmaceutical firm that both markets a suite of dermatology and pain-management products (e.g., Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend) and advances a diversified pipeline spanning injectable therapies, oncology monoclonal antibodies, gene-therapy candidates, and vaccine platforms.
Beyond its commercial portfolio, FBIO’s pipeline includes late-stage assets such as UNLOXCYT for metastatic cutaneous squamous cell carcinoma, Olafertinib for EGFR-mutated NSCLC, and CAEL-101 for AL amyloidosis, as well as early-stage programs targeting gout (Dotinurad), glioblastoma (MB-101/108/109), B-cell NHL (MB-106), and gene-therapy vectors (AAV-ATP7A, AVTS-001). The company’s strategy relies on multiple partnership and acquisition pathways to broaden its addressable market.
As of the most recent quarter, FBIO reported a market capitalization of roughly $300 million and a cash runway of ~ $150 million, giving it roughly 12-month liquidity at current burn rates. The broader biotech sector is benefiting from a 7 % YoY increase in R&D spending and a 4 % rise in FDA approvals for novel therapies, which supports higher valuation multiples for companies with diversified pipelines like FBIO.
For a deeper quantitative view, you may find ValueRay’s analyst dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 3.99m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 44.02 > 1.0 |
| NWC/Revenue: 103.4% < 20% (prev 25.56%; Δ 77.87% < -1%) |
| CFO/TA -0.36 > 3% & CFO -66.1m > Net Income 3.99m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.1m) vs 12m ago 68.05% < -2% |
| Gross Margin: 65.83% > 18% (prev 0.62%; Δ 6521 % > 0.5%) |
| Asset Turnover: 40.39% > 50% (prev 49.18%; Δ -8.79% > 0%) |
| Interest Coverage Ratio: -4.25 > 6 (EBITDA TTM -38.8m / Interest Expense TTM 10.3m) |
Altman Z'' -15.00
| A: 0.36 (Total Current Assets 118.5m - Total Current Liabilities 54.1m) / Total Assets 181.4m |
| B: -4.02 (Retained Earnings -730.1m / Total Assets 181.4m) |
| C: -0.28 (EBIT TTM -43.9m / Avg Total Assets 154.2m) |
| D: -6.28 (Book Value of Equity -730.1m / Total Liabilities 116.2m) |
| Altman-Z'' Score: -19.30 = D |
Beneish M -1.86
| DSRI: 1.68 (Receivables 18.1m/10.8m, Revenue 62.3m/62.5m) |
| GMI: 0.94 (GM 65.83% / 61.85%) |
| AQI: 1.45 (AQ_t 0.26 / AQ_t-1 0.18) |
| SGI: 1.00 (Revenue 62.3m / 62.5m) |
| TATA: 0.39 (NI 3.99m - CFO -66.1m) / TA 181.4m) |
| Beneish M-Score: -1.86 (Cap -4..+1) = B |
What is the price of FBIO shares?
Over the past week, the price has changed by +3.81%, over one month by -25.34%, over three months by +26.25% and over the past year by +86.86%.
Is FBIO a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | 228.7% |
| Analysts Target Price | 10.8 | 228.7% |
| ValueRay Target Price | 3.3 | 1.2% |
FBIO Fundamental Data Overview February 05, 2026
P/S = 1.5394
P/B = 1.7503
P/EG = -0.1
Revenue TTM = 62.3m USD
EBIT TTM = -43.9m USD
EBITDA TTM = -38.8m USD
Long Term Debt = 47.8m USD (from longTermDebt, last quarter)
Short Term Debt = 7.75m USD (from shortTermDebt, last quarter)
Debt = 68.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -17.9m USD (from netDebt column, last quarter)
Enterprise Value = 78.0m USD (95.9m + Debt 68.3m - CCE 86.2m)
Interest Coverage Ratio = -4.25 (Ebit TTM -43.9m / Interest Expense TTM 10.3m)
EV/FCF = -1.18x (Enterprise Value 78.0m / FCF TTM -66.1m)
FCF Yield = -84.81% (FCF TTM -66.1m / Enterprise Value 78.0m)
FCF Margin = -106.2% (FCF TTM -66.1m / Revenue TTM 62.3m)
Net Margin = 6.40% (Net Income TTM 3.99m / Revenue TTM 62.3m)
Gross Margin = 65.83% ((Revenue TTM 62.3m - Cost of Revenue TTM 21.3m) / Revenue TTM)
Gross Margin QoQ = 67.36% (prev 69.91%)
Tobins Q-Ratio = 0.43 (Enterprise Value 78.0m / Total Assets 181.4m)
Interest Expense / Debt = 3.54% (Interest Expense 2.42m / Debt 68.3m)
Taxrate = 0.29% (26.0k / 8.85m)
NOPAT = -43.7m (EBIT -43.9m * (1 - 0.29%)) [loss with tax shield]
Current Ratio = 2.19 (Total Current Assets 118.5m / Total Current Liabilities 54.1m)
Debt / Equity = 1.22 (Debt 68.3m / totalStockholderEquity, last quarter 55.9m)
Debt / EBITDA = 0.46 (negative EBITDA) (Net Debt -17.9m / EBITDA -38.8m)
Debt / FCF = 0.27 (negative FCF - burning cash) (Net Debt -17.9m / FCF TTM -66.1m)
Total Stockholder Equity = 36.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.58% (Net Income 3.99m / Total Assets 181.4m)
RoE = 11.02% (Net Income TTM 3.99m / Total Stockholder Equity 36.2m)
RoCE = -52.26% (EBIT -43.9m / Capital Employed (Equity 36.2m + L.T.Debt 47.8m))
RoIC = -47.45% (negative operating profit) (NOPAT -43.7m / Invested Capital 92.2m)
WACC = 6.32% (E(95.9m)/V(164.2m) * Re(8.31%) + D(68.3m)/V(164.2m) * Rd(3.54%) * (1-Tc(0.00)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 105.9%
Fair Price DCF = unknown (Cash Flow -66.1m)
EPS Correlation: 8.96 | EPS CAGR: 11.90% | SUE: 0.15 | # QB: 0
Revenue Correlation: -32.92 | Revenue CAGR: -0.95% | SUE: -0.30 | # QB: 0
EPS next Year (2026-12-31): EPS=0.01 | Chg30d=+2.130 | Revisions Net=+1 | Growth EPS=-96.8% | Growth Revenue=+49.3%